MEDINET Co., Ltd.

Tokyo Stock Exchange 2370.T

MEDINET Co., Ltd. Return on Assets (ROA) for the year ending September 30, 2024: -22.40%

MEDINET Co., Ltd. Return on Assets (ROA) is -22.40% for the year ending September 30, 2024, a 12.22% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

MEDINET Co., Ltd. Return on Assets (ROA) for the year ending September 30, 2023 was -25.52%, a -23.69% change year over year.
MEDINET Co., Ltd. Return on Assets (ROA) for the year ending September 30, 2022 was -20.63%, a -31.56% change year over year.
MEDINET Co., Ltd. Return on Assets (ROA) for the year ending September 30, 2021 was -15.68%, a 2.22% change year over year.
MEDINET Co., Ltd. Return on Assets (ROA) for the year ending September 30, 2020 was -16.04%, a 37.80% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Tokyo Stock Exchange: 2370.T

MEDINET Co., Ltd.

CEO	Kanenao Kubushiro
IPO Date	Oct. 8, 2003
Location	Japan
Headquarters	TRC Center Building
Employees	92
Sector	Healthcare
Industries Biotechnology 3D Printing Medical Instruments Robotics

Description

MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. Further, the company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years